Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wuling capsule plus psychotherapy for mild to moderate anxiety and depression in adolescents
ChiCTR2000040492Phase 4Not yet recruiting
- Sponsor
- Huzhou Hospital of Traditional Chinese Medicine
- Start
- Dec 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of wulingshen in major depressive disorder (MDD), anxiety disorder and sleep disorder (2 arms), sponsored by Huzhou Hospital of Traditional Chinese Medicine. Primary endpoints: Hamilton Depression Scale-17 items (HAMD-17) and Hamilton Anxiety Scale-14 items (HAMA-14). Planned start Dec 2020; status: not yet recruiting.
02
Drugs
wulingshen
03
Conditions
major depressive disorder (MDD)anxiety disordersleep disorder
Beyond the preview
Go deeper on ChiCTR2000040492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040492.